Adolescent Idiopathic Scoliosis ADECYL

TOMORROW´S HEALTHCARE, TODAY

EpiDisease SL is an innovative Spanish biotechnology company that has positioned itself as a pioneer in the research and development of clinical tools based on genetic and epigenetic advances. With over 10 years of dedication and effort, EpiDisease SL is committed to delivering solutions that bring the healthcare of the future to the present day. Its flagship product, ScoliGEN, is a clear example of its cutting-edge scientific work, offering a test that enables more precise and personalized management of children with AIS.

At EpiDisease, science and health come together to transform medical care and give patients the best opportunities for their well-being.

At EpiDisease SL, we are excited to announce our collaboration with ADECyL to offer cutting-edge in vitro diagnostic (IVD) tools: ScoliGEN and ScoliMIR. These innovative solutions, developed after 10 years of research and development, are specifically designed for patients with adolescent idiopathic scoliosis (AIS) and their families. The availability of ScoliGEN and ScoliMIR at Clínica Corachan represents a global milestone in the integration of genetics and epigenetics in scoliosis management. These tools enable a precision and personalized approach, providing physicians with valuable information that can guide clinical decisions and improve outcomes and quality of life for children affected by this condition, and their families.

The ADECyL physician: Dr. Roberto Escudero

Dr. Roberto Escudero Marcos holds a degree in Medicine and Surgery from the University of Valladolid (2000–2006) and is a Specialist in Orthopedic Surgery and Traumatology. He is part of the Spine Surgery Unit at the Río Hortega University Hospital. He also holds a PhD in Medicine from the University of Valladolid, with a doctoral thesis on hip fractures in the elderly, graded Summa Cum Laude.

What are ScoliGEN and ScoliMIR?

ScoliGEN: This genetic tool evaluates the genetic profile, identifying variants that may influence the progression of scoliosis. With this information, physicians can personalize treatment plans for each child and more effectively plan for how the disease is likely to evolve.

ScoliGEN is currently available

ADECyL members enjoy a 50% discount voucher for the ScoliGEN test. Ask ADECyL for the code.

ScoliMIR: This epigenetic tool provides information on how environmental and lifestyle factors can affect gene expression related to scoliosis. With this information, physicians can diagnose and predict the progression of the spine, as well as monitor the effectiveness of conservative interventions, adapting, optimizing, and personalizing their approach for each case.

ScoliMIR is currently under regulatory review. It is expected to be commercially available for patients in the fourth quarter of 2024.

A Personalized Approach for Each Patient

The collaboration between EpiDisease SL and Clínica Corachan not only represents a breakthrough in medical technology, but also reflects our shared commitment to improving the quality of life for young people with AIS. By bringing the power of genetics and epigenetics closer to treatment, we are empowering physicians and families to make informed, data-driven decisions. We are excited about the future and the positive impact that ScoliGEN and ScoliMIR will have on the lives of patients and their families. Together, we are paving the way for a more effective and personalized approach to managing adolescent idiopathic scoliosis. For more information on how these tools can benefit your family, feel free to contact Dr. Judith Sánchez Raya.